<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02626572</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-47445-011</org_study_id>
    <secondary_id>2014‐001519‐38</secondary_id>
    <nct_id>NCT02626572</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms</brief_title>
  <official_title>Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the efficacy and safety of S47445 versus placebo in
      patients with Alzheimer's disease at mild to moderate stages with depressive symptoms. An
      optional 28-week extension period will be performed to evaluate safety/tolerance and efficacy
      of S47445 in co-administration with donepezil.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline on 11-item ADAS-Cog</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Cognition criterion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living: Disability Assessment for Dementia (DAD)</measure>
    <time_frame>baseline, week 12, week 24 and week 52</time_frame>
    <description>Key secondary efficacy criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition: 13-item ADAS-Cog</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 38 and week 52</time_frame>
    <description>Other secondary efficacy criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition: Mini-Mental State Examination (MMSE)</measure>
    <time_frame>baseline, week 12, week 24 and week 52</time_frame>
    <description>Other secondary efficacy criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms: Cornell Scale for Depression in Dementia (CSDD)</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 38 and week 52</time_frame>
    <description>Other secondary efficacy criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioural signs and symptoms: Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>baseline, week 4, week 12, week 24 and week 52</time_frame>
    <description>Other secondary efficacy criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Clinic Assessment of Change: Alzheimer's Disease Cooperative Studies-Clinical Global Impression of Change (ADCS-CGIC)</measure>
    <time_frame>baseline, week 24 and week 52</time_frame>
    <description>Other secondary efficacy criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality: Gait task (GT), measure of speed of walking (unit= meters/ seconds)</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 38 and week 52</time_frame>
    <description>Other secondary efficacy criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: heart rate</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 38 and week 52</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: body temperature</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 38 and week 52</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: blood pressure</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 38 and week 52</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: body weight</measure>
    <time_frame>baseline, week 12, week 24, week 38 and week 52</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 38 and week 52</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological laboratory parameters: number of participants with abnomal laboratory values</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 38 and week 52</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cornell Scale for Depression in Dementia (CSDD, suicide item - item 16)</measure>
    <time_frame>baseline, week 4, week 12, week 24, week 28, week 38 and week 52</time_frame>
    <description>Safety criterion</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>S47445 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S47445 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S47445 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S47445 5mg</intervention_name>
    <description>S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).</description>
    <arm_group_label>S47445 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S47445 15mg</intervention_name>
    <description>S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).</description>
    <arm_group_label>S47445 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S47445 50mg</intervention_name>
    <description>S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).</description>
    <arm_group_label>S47445 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out-patients

          -  Able to perform neuropsychological tests

          -  Have a responsible informant

          -  DSM-IV-TR criteria for Dementia of the Alzheimer's Disease Type

          -  Mini mental State Examination (MMSE) = 15-24 both inclusive

          -  National Institute of Mental Health (NIMH) provisional criteria for depression in AD
             (NIMH-dAD)

          -  Cornell Scale for Depression in Dementia total score &gt; or = 8

          -  Patients who have never been treated with AD treatments or patients who have stopped
             AD treatment whatever the reason

          -  Patients either not currently treated with an antidepressant or patients being treated
             with an antidepressant at the recommended dose for at least 8 weeks without clinical
             efficacy, who can stop this treatment according to the investigator's opinion.

        Exclusion Criteria:

          -  Patients not able to read or write

          -  Patients having participated in a study testing disease modifying therapy for AD, or
             in another study with administration of investigational drug or device within the
             previous 3 months prior to selection visit

          -  Depressive symptoms that, in investigator's judgment, are clearly due to a medical
             condition other than AD, or are a direct result of non-mood related dementia symptoms

          -  History of epilepsy or solitary seizure

          -  Medical history of Major Depressive Disorder more than 3 years before onset of the
             disease, treated with antidepressive drugs or electroconvulsive therapy

          -  Severe or unstable disease of any type that could interfere with safety and efficacy
             assessments

          -  Alcohol abuse or drug abuse or addiction, as judged by the clinician (excluding
             nicotine)

          -  Clinically relevant lactose intolerance

          -  Antidepressant treatment not stopped for at least 3 weeks before inclusion

          -  Significant worsening of depressive symptoms or high suicidal risk according to
             investigator's judgment

          -  For optional extension phase: medically instable Chronic Obstructive Pulmonary Disease
             and asthma, known hypersensitivity to donepezil hydrochloride or piperidine
             derivatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Trial Tech Tecnologia em Pesquisa com Medicamentos</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Walter Cantidio</name>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilive - Centro de Pesquisas Clinicas</name>
      <address>
        <city>Maringa</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Oswaldo Cruz</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Américo Bairral de Psiquiatria, Centro de Pesquisa</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIFESP - Universidade Federal de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Sveti Georgi</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Sofia, Aleksandrovska hospital</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital of Cardiology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Sveti Naum, Clinic of Neurology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Sveta Marina</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Oriente</name>
      <address>
        <city>Antofagasta</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedica Research Group</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Especialidades Medicas LYS</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santiago Oriente</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Anne s.r.o. Psychiatricka ambulance</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain-Soultherapy s.r.o.</name>
      <address>
        <city>Kladno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bialbi s.r.o.</name>
      <address>
        <city>Litomerice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AD71 s.r.o. Psychiatricka ambulance - Sudkova</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLINTRIAL s.r.o.</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FORBELI s.r.o., Neurologicka ambulance</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land GmbH Neurologische Klinik</name>
      <address>
        <city>Altenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatrisches Facharztzentrum Stiepel</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes, Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Homburg / Saar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISPG Institut für Studien zur Psychischen Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmakologisches Studienzentrum Chemnitz GmbH</name>
      <address>
        <city>Mittweida</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somni Bene, Institut fuer Medizinische Forschung und Schlafmedizin Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik ULM, Poliklinik Neurologie</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Westerstede</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Neurologiai Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy Gyula Korhaz es Rendelointezet</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaszary Kolos Korhaz Esztergom Neurologiai Osztaly</name>
      <address>
        <city>Esztergom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz Pszihiatriai, Mentalhygienes es Addiktologiai Osztaly</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Kalocsa</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B-A-Z Megyei Korhaz es Egyetemi Oktato Korhaz Stroke, Er- es Neurologiai, Toxikologiai Osztaly</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josa Andras Oktatokorhaz Pszihiatriai Osztaly</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem, Klinikai Kozpont Pszich. es Pszichoter. Klinika</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent-Gyorgyi Albert Klinikai Kozpont Pszichiatriai Klinika</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz Pszichiatriai Osztaly</name>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Clinic Ochanomizu</name>
      <address>
        <city>Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showakai Clinic</name>
      <address>
        <city>Kagoshima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow &amp; Sea Hospital</name>
      <address>
        <city>Karatsu-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokan Clinic</name>
      <address>
        <city>Kawasaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Medical Corporation Kojunkai Daido Hospital</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakano General Hospital</name>
      <address>
        <city>Nakano-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Saitama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Setagaya-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seishinkai Okehazama Hospital</name>
      <address>
        <city>Toyoake-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Biomedico de Investigacion</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Clinicos Y Especialidades Medicas Sc</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Nuevo León</name>
      <address>
        <city>Nuevo León</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Saltillo</name>
      <address>
        <city>Saltillo</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Centrum Kultury, Higieny I Zdrowia Psychicznego</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii Centrum Neurologii Klinicznej</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Neuromed M. i M. Nastaj Sp. Partnerska</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osrodek Alzheimerowski Sp. z o.o.</name>
      <address>
        <city>Scinawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SENIOR Poradnia Psychogeriatryczna</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Neuroprotect</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interregional Clinico-Diagnostical Centre</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University n.a.I.M. Sechenov Clinic of Neurology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Center of Mental Health Sect of AD and associated disord. Dpt of gerontopsychiatry</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Center of Mental Health Sect of psychosis of elderly ages Dpt of gerontopsychiatry</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City geriatric medico-social centre</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Military Academy n.a.S.M.Kirov</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychoneuropathology Dispensary N 10</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Co Ltd &quot;LION-MED&quot;</name>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INVESTA, spol. s r. o. Psychiatricka ambulancia</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NsP Svatej Barbory Psychiatricke oddelenie</name>
      <address>
        <city>Roznava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iatros International</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flexivest Fourteen Research Centre</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umhlanga Hospital</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excellentis Clinical Trial Consultants</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Clinical Research</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denmar Hospital</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset West Trial Centre</name>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

